MedTrace Logo

Comparison of Viral Particle Dispersion Following Administration of an MDI or Nebulizer in Subjects With COVID-19

NCT04681079 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 14

Last updated 2022-01-28

No results posted yet for this study

Summary

A randomized, 2-period crossover, single-center, open-label study for viral sample collection. After initiation of inhaled therapy with nebulizer or MDI, cascade impactors and surface samplers will be used to assess viral loads in rooms of subjects with COVID-19.

Conditions

Interventions

DRUG

albuterol sulfate (MDI)

albuterol sulfate inhalation aerosol delivered via metered-dose inhaler (MDI) with spacer

DRUG

albuterol sulfate (nebulizer)

albuterol sulfate inhalation aerosol delivered via nebulizer with filtered mouthpiece

Sponsors & Collaborators

  • Theravance Biopharma

    lead INDUSTRY

Principal Investigators

  • Medical Monitor · Theravance Biopharma

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-04
Primary Completion
2021-11-22
Completion
2022-01-18

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04681079 on ClinicalTrials.gov